aTyr Pharma (LIFE) Sees Unusually-High Trading Volume

Shares of aTyr Pharma Inc (NASDAQ:LIFE) saw strong trading volume on Thursday . 1,308,183 shares changed hands during trading, an increase of 192% from the previous session’s volume of 447,423 shares.The stock last traded at $0.68 and had previously closed at $0.64.

A number of analysts recently issued reports on the company. Piper Jaffray Companies decreased their price objective on aTyr Pharma from $3.00 to $1.80 and set an “overweight” rating on the stock in a research note on Monday, October 8th. Citigroup upgraded aTyr Pharma from a “sell” rating to a “neutral” rating and decreased their price objective for the company from $1.00 to $0.75 in a research note on Thursday, August 16th. BMO Capital Markets decreased their price objective on aTyr Pharma from $2.00 to $1.00 and set a “hold” rating on the stock in a research note on Wednesday, August 15th. Finally, Zacks Investment Research lowered aTyr Pharma from a “buy” rating to a “hold” rating in a research note on Tuesday, July 17th. One investment analyst has rated the stock with a sell rating, four have given a hold rating and one has issued a buy rating to the stock. The stock currently has a consensus rating of “Hold” and an average target price of $1.64.

The company has a market capitalization of $18.21 million, a price-to-earnings ratio of -0.36 and a beta of 2.88. The company has a quick ratio of 5.96, a current ratio of 5.96 and a debt-to-equity ratio of 0.26.

aTyr Pharma (NASDAQ:LIFE) last announced its earnings results on Tuesday, August 14th. The biotechnology company reported ($0.35) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.34) by ($0.01). Equities analysts forecast that aTyr Pharma Inc will post -1.29 EPS for the current year.

In other aTyr Pharma news, CFO Jill Marie Broadfoot bought 64,000 shares of the firm’s stock in a transaction on Thursday, September 20th. The shares were acquired at an average cost of $0.83 per share, for a total transaction of $53,120.00. The acquisition was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, Director Paul Schimmel bought 42,749 shares of the firm’s stock in a transaction on Tuesday, September 4th. The stock was acquired at an average price of $0.74 per share, for a total transaction of $31,634.26. The disclosure for this purchase can be found here. Insiders acquired a total of 297,160 shares of company stock worth $225,398 over the last 90 days. Corporate insiders own 25.00% of the company’s stock.

An institutional investor recently raised its position in aTyr Pharma stock. Renaissance Technologies LLC grew its position in shares of aTyr Pharma Inc (NASDAQ:LIFE) by 37.6% during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 533,861 shares of the biotechnology company’s stock after purchasing an additional 145,761 shares during the quarter. Renaissance Technologies LLC owned approximately 1.79% of aTyr Pharma worth $486,000 as of its most recent SEC filing. 44.54% of the stock is currently owned by institutional investors.

TRADEMARK VIOLATION NOTICE: “aTyr Pharma (LIFE) Sees Unusually-High Trading Volume” was originally posted by Sports Perspectives and is the property of of Sports Perspectives. If you are reading this report on another website, it was copied illegally and republished in violation of U.S. & international copyright & trademark legislation. The legal version of this report can be read at https://sportsperspectives.com/2018/11/09/atyr-pharma-life-sees-unusually-high-trading-volume.html.

aTyr Pharma Company Profile (NASDAQ:LIFE)

aTyr Pharma, Inc, a clinical stage biotechnology company, engages in the discovery and development of medicines for the treatment of cancer and lung disease in the United States. The company's therapeutic candidate pipeline that includes ATYR1923 candidate, an agonist of the Resokine pathway that is in Phase I clinical trial designed to temper immune engagement in interstitial lung diseases; and ORCA program, a preclinical research stage program that targets immuno-oncology pathway using antibodies to enhance the immune response in tumor settings.

Featured Article: Hedge Funds – How They Work For Investors

Receive News & Ratings for aTyr Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for aTyr Pharma and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply